Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

Compare

972 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELDN Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Eledon

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELDN Stock 12 Month Forecast

Average Price Target

$7.75

▲(375.46% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is $7.75 with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 375.46% change from the last price of $1.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.756923076923077,5.193846153846154,5.630769230769231,6.067692307692308,6.504615384615384,6.941538461538462,7.378461538461538,7.815384615384616,8.252307692307692,8.689230769230768,9.126153846153846,9.563076923076924,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.583846153846154,4.8476923076923075,5.111538461538462,5.375384615384616,5.639230769230769,5.903076923076924,6.166923076923077,6.430769230769231,6.694615384615385,6.958461538461538,7.222307692307693,7.486153846153846,{"y":7.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.295384615384616,4.270769230769231,4.246153846153846,4.2215384615384615,4.196923076923077,4.172307692307692,4.147692307692308,4.1230769230769235,4.098461538461539,4.073846153846154,4.049230769230769,4.024615384615385,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$7.75

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Vamil Divan

Guggenheim

$9→$8

Buy

390.80%

Upside

Reiterated

11/17/25

Eledon Pharmaceuticals price target lowered to $8 from $9 at GuggenheimEledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

Rami Katkhuda

LifeSci Capital

Buy

145.40%

Upside

Reiterated

11/16/25

Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy RatingEledon (Nasdaq: ELDN) reported Q3 2025 earnings aer Friday’s close, ﬁnishing the period with $93.4M in cash, cash equivalents, and short- term investments; the Company also completed a $57.5M ﬁnancing last week to support the connued development of tegoprubart in transplantaon.

Yi Chen

H.C. Wainwright

Buy

452.15%

Upside

Reiterated

11/10/25

H.C. Wainwright Remains a Buy on Eledon Pharmaceuticals (ELDN)In the wake of this update, we reiterate our Buy rating and $9 price target.

Robert LeBoyer

Noble Financial

$10

Buy

513.50%

Upside

Reiterated

11/10/25

Noble Financial Keeps Their Buy Rating on Eledon Pharmaceuticals (ELDN)We are reiterating our Outperform rating and $10 price target.

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Eledon Pharmaceuticals (NASDAQ: ELDN) and AMN Healthcare Services (NYSE: AMN)

Thomas Smith

Leerink Partners

Buy

390.80%

Upside

Reiterated

08/15/25

Eledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top AnalystELEDON reported 2Q25 results and reaffirmed its outlook, leading us to reiterate our Outperform rating with a price target of $8.

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

07/10/25

Cantor Fitzgerald Keeps Their Buy Rating on Eledon Pharmaceuticals (ELDN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Vamil Divan

Guggenheim

$9→$8

Buy

390.80%

Upside

Reiterated

11/17/25

Eledon Pharmaceuticals price target lowered to $8 from $9 at GuggenheimEledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

Rami Katkhuda

LifeSci Capital

Buy

145.40%

Upside

Reiterated

11/16/25

Yi Chen

H.C. Wainwright

Buy

452.15%

Upside

Reiterated

11/10/25

H.C. Wainwright Remains a Buy on Eledon Pharmaceuticals (ELDN)In the wake of this update, we reiterate our Buy rating and $9 price target.

Robert LeBoyer

Noble Financial

$10

Buy

513.50%

Upside

Reiterated

11/10/25

Noble Financial Keeps Their Buy Rating on Eledon Pharmaceuticals (ELDN)We are reiterating our Outperform rating and $10 price target.

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Eledon Pharmaceuticals (NASDAQ: ELDN) and AMN Healthcare Services (NYSE: AMN)

Thomas Smith

Leerink Partners

Buy

390.80%

Upside

Reiterated

08/15/25

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

07/10/25

Cantor Fitzgerald Keeps Their Buy Rating on Eledon Pharmaceuticals (ELDN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eledon Pharmaceuticals

1 Month

xxx

Success Rate

5/14 ratings generated profit

Average Return

-1.38%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 35.71% of your transactions generating a profit, with an average return of -1.38% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+5.45%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +5.45% per trade.

1 Year

Robert LeBoyerNoble Financial

Not Ranked

Success Rate

7/14 ratings generated profit

Average Return

+14.74%

reiterated a buy rating 21 days ago

Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +14.74% per trade.

2 Years

xxx

Success Rate

7/24 ratings generated profit

Average Return

-18.98%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 29.17% of your transactions generating a profit, with an average return of -18.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELDN Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELDN has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ELDN average Analyst price target in the past 3 months is 7.75.

Each month's total comprises the sum of three months' worth of ratings.

ELDN Financial Forecast

ELDN Earnings Forecast

Next quarter’s earnings estimate for ELDN is -$0.20 with a range of -$0.26 to -$0.16. The previous quarter’s EPS was -$0.21. ELDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ELDN has Performed in-line its overall industry.

No data currently available

ELDN Sales Forecast

Next quarter’s sales forecast for ELDN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ELDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ELDN has Performed in-line its overall industry.

ELDN Stock Forecast FAQ

What is ELDN’s average 12-month price target, according to analysts?

Based on analyst ratings, Eledon Pharmaceuticals’s 12-month average price target is 7.75.

What is ELDN’s upside potential, based on the analysts’ average price target?

Eledon Pharmaceuticals has 375.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELDN a Buy, Sell or Hold?

Eledon Pharmaceuticals has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Eledon Pharmaceuticals’s price target?

The average price target for Eledon Pharmaceuticals is 7.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 375.46% Increase from the current price of $1.63.

What do analysts say about Eledon Pharmaceuticals?

Eledon Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ELDN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

ELDN Analyst Ratings

ELDN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eledon Pharmaceuticals

ELDN Analyst Recommendation Trends

ELDN Financial Forecast

ELDN Earnings Forecast

ELDN Sales Forecast

ELDN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts